Loading tape…Loading tape…
REGN
REGN
REGN
REGN NASDAQ
A class action lawsuit deadline has been announced for investors in Regeneron Pharmaceuticals, Inc., set for September 14, 2026. Against the backdrop of these legal matters, the company holds a market capitalization of $85,273,369,840 and recorded a full-year revenue of $14,342,900,000. Additionally, Regeneron maintains a P/E ratio of 19.764087870105065, an EPS TTM of 41.86363636363637, and a free cash flow yield of 4.130128792386422%.
Based on prnewswire.comINVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline
REGN UPCOMING DEADLINE: SueWallSt Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm
REGN EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
REGN 2-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - HBSS
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Stonks with professional market data, charts beside chat, and your portfolio context.
Tape shows delayed public market data. Not investment advice.